Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome (NCT07278375) | Clinical Trial Compass
RecruitingNot Applicable
Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome
United States796 participantsStarted 2025-12-09
Plain-language summary
The goal of this observational study is to learn how two medicines used in routine care-buprenorphine and morphine-affect recovery in newborns (≥36 weeks' gestation) with Neonatal Opioid Withdrawal Syndrome (NOWS). The main questions it aims to answer are:
1. Do infants treated with buprenorphine become medically ready for discharge sooner than those treated with morphine?
2. Does one treatment lead to better overall clinical outcomes than the other?
Researchers will compare infants who received buprenorphine with infants who received morphine to see whether one treatment helps babies recover more quickly.
Participants will not be asked to do anything. Instead, the study team will collect information already documented in the infant's and mother's medical records securely without any contact or changes to clinical care.
No new medicines, procedures, or visits are involved. This study only reviews existing clinical data to better understand which commonly used treatment may support faster recovery for newborns with NOWS.
Who can participate
Age range0 Minutes
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Infant is ≥ 36 weeks' gestational age
✓. Infant had antenatal opioid exposure identified by at least one of the following:
✓. History of maternal opioid use during the second and/or third trimester of pregnancy as noted in the mother's or infant's medical record;
✓. Positive maternal toxicology screen for opioids during the second or third trimester of pregnancy; and/or
✓. Positive infant toxicology screen for opioids during the initial hospital stay.
✓. The infant is being assessed and managed for NOWS at an eligible study site.
✓. The infant is at risk for pharmacologic treatment for NOWS defined by either of the following:
✓. Infant met all inclusion criteria on or after March 25, 2024.
Exclusion criteria
✕. Infant has major congenital anomalies.
✕
What they're measuring
1
Time from birth until infant meets criteria for medically ready for discharge (count)
Timeframe: From date of birth until date of infant meeting criteria for medically ready for discharge (estimated to be < 90 days).
. Infant has neonatal encephalopathy (inclusive of hypoxic ischemic encephalopathy), a metabolic disorder, stroke, intracranial hemorrhage, or meningitis diagnosed prior to the initiation of pharmacologic treatment.
✕. Infant is receiving respiratory support (any positive pressure or oxygen therapy) at 48 hours of age.
✕. Infant has undergone major surgical intervention prior to or at 48 hours of age.
✕. Infant has postnatal opioid exposure prior to the initiation of pharmacologic treatment for NOWS.
✕. Infant was outborn and pharmacologic treatment was initiated at the transferring hospital.